When a new drug is introduced to the Canadian market, the manufacturer may submit a request to the Newfoundland and Labrador Prescription Drug Program (NLPDP) that it be considered for possible coverage by the Drug Program. A drug manufacturer may submit a request to NLPDP at any time. Reviews of drug submissions are conducted in the order they are received and are added as they are approved. Only drug products which are valid therapeutic agents, with proven clinical effectiveness will be considered for coverage under the Program. The cost of therapy and clinical efficacy relative to other drug therapies is considered; an increased cost may be justified if the drug produces better clinical results in the patient population.
When a drug product is accepted for coverage under the Program, they are classified as either Open Benefit or Special Authorization. A detailed list of the coverage status is available for download.
Adobe® Acrobat® Reader software can be used for viewing PDF documents. Download Acrobat® Reader for free .